Andrew L Mellor, Age 632021 Autumn Chase, Augusta, GA 30907

Andrew Mellor Phones & Addresses

2021 Autumn Chase, Augusta, GA 30907 (706) 868-9161

1406 Woodhill Trl, Augusta, GA 30909 (706) 729-1488

Social networks

Andrew L Mellor
Andrew L Mellor

Linkedin

Work

Company: Georgia health sciences university 2002 to 2013 Position: Director, immunotherapy center

Education

Degree: PhD School / High School: University of London 1976 to 1979 Specialities: Tumour Virology

Awards

Bradley-Turner & Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics

Interests

inflammation, immune tolerance, T cell immunobiology, immunotherapy to treat cancer, infectious/autoimmune diseases & transplant patients

Industries

Research

Mentions for Andrew L Mellor

Resumes

Resumes

Andrew Mellor Photo 1

Director, Immunotherapy Center At Georgia Health Sciences University

Position:
Director, Immunotherapy Center at Georgia Health Sciences University, Professor of Medicine at Georgia Health Sciences University
Location:
Augusta, Georgia
Industry:
Research
Work:
Georgia Health Sciences University since 2002
Director, Immunotherapy Center
Georgia Health Sciences University since 1995
Professor of Medicine
National Institute for Medical Research 1988 - 1995
Senior Scientist
CRC Northwick Park Hosptial 1984 - 1987
Scientist
Biogen 1982 - 1984
Research Scientist
National Institute for Medical Research 1979 - 1982
Postdoctoral fellow
Education:
University of London 1976 - 1979
PhD, Tumour Virology
University of Cambridge 1973 - 1976
BA (MA), Natural Sciences Tripos (Biochemistry)
Interests:
inflammation, immune tolerance, T cell immunobiology, immunotherapy to treat cancer, infectious/autoimmune diseases & transplant patients
Honor & Awards:
Bradley-Turner & Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics

Publications

US Patents

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
6451840, Sep 17, 2002
Filed:
Dec 4, 1998
Appl. No.:
09/206274
Inventors:
David Munn - Augusta GA
Andrew Mellor - Augusta GA
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
C07D40102
US Classification:
514419, 4242781
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes.

Chemokine Receptor Antagonists As Therapeutic Agents

US Patent:
2009004, Feb 12, 2009
Filed:
Oct 6, 2008
Appl. No.:
12/287205
Inventors:
David H. Munn - Augusta GA,
Andrew L. Mellor - Martinez GA,
Stephen C. Peiper - Augusta GA,
International Classification:
A61K 39/395
US Classification:
4241731
Abstract:
The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3α. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.

Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance

US Patent:
2013032, Dec 5, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/840377
Inventors:
ANDREW L. MELLOR - AUGUSTA GA,
JEFFREY ROBERTS LEE - MARTINEZ GA,
Assignee:
GEORGIA HEALTH SCIENCES UNIVERSITY - AUGUST GA
International Classification:
C12N 5/0784
US Classification:
435325
Abstract:
The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

Regulation Of T Cell-Mediated Immunity By Tryptophan

US Patent:
2012028, Nov 15, 2012
Filed:
May 21, 2012
Appl. No.:
13/476183
Inventors:
David MUNN - Augusta GA,
Andrew Mellor - Augusta GA,
Assignee:
Georgia Health Sciences University - Augusta GA
International Classification:
A61K 38/44
A61P 37/02
A61K 38/19
US Classification:
424 851, 424 944
Abstract:
A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and other types of transplantation. Inhibitors of IDO can be used to activate T cells. Inhibiting tryptophan degradation, or supplementing tryptophan concentration, can be used in addition to, or in place of, inhibitors of IDO. Increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. One can manipulate local tryptophan concentrations, and/or modulate the activity of the high affinity tryptophan transporter, and/or administer tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as MCSF, IFNγ, alone or in combination with antigen or other cytokines.

Indoleamine 2,3-Dioxygenase Pathways In The Generation Of Regulatory T Cells

US Patent:
2012014, Jun 7, 2012
Filed:
Nov 30, 2011
Appl. No.:
13/308060
Inventors:
Wei Chen - Edina MN,
Bruce R. Blazar - Golden Valley MN,
David Munn - Augusta GA,
Andrew Mellor - Augusta GA,
International Classification:
A61K 31/405
A61P 37/06
A61P 37/04
US Classification:
514419
Abstract:
The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.

Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance

US Patent:
2012014, Jun 7, 2012
Filed:
Feb 15, 2012
Appl. No.:
13/397152
Inventors:
ANDREW L. MELLOR - AUGUSTA GA,
DAVID H. MUNN - AUGUSTA GA,
JEFFREY ROBERTS LEE - MARTINEZ GA,
Assignee:
GEORGIA HEALTH SCIENCES UNIVERSITY - AUGUSTA GA
International Classification:
C12Q 1/68
C12Q 1/26
G01N 33/574
US Classification:
435 611, 435 723, 435 25
Abstract:
The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

Methods And Compositions To Enhance Vaccine Efficacy By Reprogramming Regulatory T Cells

US Patent:
2011030, Dec 15, 2011
Filed:
Apr 13, 2011
Appl. No.:
13/086090
Inventors:
David H. MUNN - Augusta GA,
Andrew L. Mellor - Augusta GA,
Madhav D. Sharma - Augusta GA,
Yukai He - Evans GA,
Assignee:
Medical College of Georgia Research Institute, Inc - Augusta GA
International Classification:
A61K 39/395
A61K 31/7088
A61P 37/02
C12N 5/0783
A61K 39/21
A61K 39/00
US Classification:
4241731, 4241991, 4241841, 435375, 514 44 R
Abstract:
The immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) is expressed by a subset of murine plasmacytoid DCs (pDCs) in tumor-draining LNs, where it can potently activate Foxp3 regulatory T cells (Tregs). We now show that IDO functions as a molecular switch in tumor-draining LNs, maintaining Tregs in their normal suppressive phenotype when IDO was active, but allowing inflammation-induced conversion of Tregs to a polyfunctional T-helper phenotype similar to proinflammatory TH17 cells when IDO was blocked. In vitro, conversion of Tregs to the TH17-like phenotype was driven by antigen-activated effector T cells, and required IL-6 produced by activated pDCs. IDO regulated this conversion by dominantly suppressing production of IL-6 in pDCs, in a GCN2-kinase dependent fashion. In vivo, using a model of established B16 melanoma, the combination of an IDO-inhibitor drug plus anti-tumor vaccine caused upregulation of IL-6 in pDCs and in situ conversion of a majority of Tregs to the TH17 phenotype, with marked enhancement of CD8 T cell activation and anti-tumor efficacy. Thus, Tregs in tumor-draining LNs can be actively re-programmed in vitro and in vivo into T-helper cells, without the need for physical depletion, and IDO serves as a key regulator of this critical conversion.

Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance

US Patent:
2010026, Oct 21, 2010
Filed:
Apr 1, 2010
Appl. No.:
12/798307
Inventors:
Andrew L. Mellor - Augusta GA,
David H. Munn - Augusta GA,
Jeffrey Roberts Lee - Martinez GA,
International Classification:
C12Q 1/68
C12Q 1/26
G01N 33/53
US Classification:
435 6, 435 25, 435 71, 435 792
Abstract:
The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

All data offered is derived from public sources. We do not verify or evaluate each piece of data, and makes no warranties or guarantees about any of the information offered. We do not possess or have access to secure or private financial information. People Background Check is not a credit reporting agency and does not offer consumer reports. None of the information offered by People Background Check is to be considered for purposes of determining any entity or person's eligibility for credit, insurance, employment, housing, or for any other purposes covered under the FCRA.